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Abstract: Multifactorial pathogenesis of non-alcoholic steatohepatitis (NASH) disease, a wide-spread
liver pathology associated with metabolic alterations triggered by hepatic steatosis, should be hit
by multitarget therapeutics. We tested a multicomponent food supplement mixture (AP-NHm),
whose components have anti-dislipidemic, antioxidant and anti-inflammatory effects, on in vitro
and in vivo models of NASH. In vitro, hepatic cells cultures were treated for 24 h with 0.5 mM
oleic acid (OA): in the co-treatment set cells were co-treated with AP-NH mixtures (AP-NHm,
1:3:10 ratio) and in the post-injury set AP-NHm was added for 48 h after OA damage. In vivo,
C57BL/6 mice were fed with high-fat diet (HFD) for 12 weeks, inducing NASH at 7th week,
and treated with AP-NHm at two dosages (1:3 ratio) in co-treatment or post-injury protocols,
while a control group was fed with a standard diet. In in vitro co-treatment protocol, alterations
of redox balance, proinflammatory cytokines release and glucose uptake were restored in a
dose-dependent manner, at highest dosages also in post-injury regimen. In both regimens, pathologic
dyslipidemias were also ameliorated by AP-NHm. In vivo, high-dose-AP-NHm-co-treated-HFD mice
dose-dependently gained less body weight, were protected from dyslipidemia, and showed a lower
liver weight. Dose-dependently, AP-NHm treatment lowered hepatic LDL, HDL, triglycerides levels
and oxidative damage; co-treatment regimen was anti-inflammatory, reducing TNF-α and IL-8 levels.
Hepatic lipidic infiltration significantly decreased in co-treated and post-injury-AP-NHm-HFD
animals. The multitarget approach with AP-NHm was effective in preventing and reducing
NASH-related pathologic features, warranting for the clinical development of this compound.
Keywords: fatty liver; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis
(NASH); polyunsaturated fatty acid (PUFA); Silybum marianum extract; choline; Tanacetum parthenium
extract; green coffee Arabic extract; dl-α-tocopheryl acetate; AP-NHm
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1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which is not associated with
excessive alcohol consumption and whose worldwide prevalence is estimated to be 25%, with regional
and sex-related differences [1–3]. In one third of cases it may progress to a more severe liver pathology
termed non-alcoholic steatohepatitis (NASH), associated with inflammation, cell injury, hepatocyte
ballooning, and liver fibrosis [4,5]. Hepatocellular lipid overload results in lipotoxicity, causing
a sublethal or lethal injury. Release of pro-inflammatory cytokines starts a feed-forward loop of
inflammation which makes it chronic and leads to hepatic tissue remodeling and fibrosis. In this
pathological picture, oxidative stress, mitochondrial dysfunction, and insulin resistance are the main
players [4]. The public health impact of NASH is major because of the high risk of life-threatening
liver-related outcomes, such as cirrhosis and hepatocellular carcinoma (HCC), as well as of major
systemic manifestations (i.e., diabetes, cardiovascular damage, etc.). Despite the significant burden of
this pathology, no therapy was approved by Federal Drug Administration (FDA) or European Medicines
Agency (EMA) and, currently, the cornerstone of NASH management is life-style modifications: eating
healthy food and doing regular exercise. Current pharmacological suggestions are based on drugs
usually addressed to treatment of type 2 diabetes or dyslipidemia, which may be administered
following strictly personalized criteria: for instance, the antioxidant vitamin E and the PPARγ-agonist
pioglitazone [6–10]. Several agents targeting specifically different stages and molecular events of this
pathology are in clinical trials [11], such as obeticholic acid (OCA), a Farnesoid X Receptor (FXR)
agonist [12,13] and elafibranor, a PPAR-α/δ agonist [14]. In the present study, we tested the curative and
preventive properties of a multi-nutraceutical formulation (AP-NHm), composed of: Silybum marianum
extract (80% silymarin), the omega-3 fatty acid docosahexaenoic acid (DHA), choline, Tanacetum
parthenium (feverfew) extract (0.1% parthenolides), green coffee Arabic extract (45% chlorogenic acid),
DL α-tocopheryl acetate (vitamin E). These compounds are or contain nutrients known to intervene
on different aspects of the disease: lipid load, inflammatory processes, oxidative unbalance and
consequent glucose metabolism alteration. Silymarin is the principal component of the medicinal
plant Silybum marianum: in a juvenile model of NASH, its supplementation to the diet ameliorated
glucose and lipid profiles, reduced fibrosis, inflammation and oxidation [15]. Docosahexaenoic acid
(DHA) is an omega-3 fatty acid deriving from marine sources; according with previous evidence, it is
low-concentrated in the blood and liver of NASH patients and its supplementation in pre-clinical
and clinical studies inhibited the progression of hepatic steatosis and showed hypotriglyceridemic
properties, thus ameliorating nutritional NAFLD [16,17]. Choline is an indispensable nutrient whose
metabolism is regulated by the liver and whose dietary deficiency paves the way to fatty liver
and its more aggressive declinations: European Food Safety Agency (EFSA) defined it as the food
ingredient necessary for a “healthy functioning liver” [18,19]. Parthenolide is the main sesquiterpene
lactone of the curative plant Tanacetum parthenium (feverfew): it is a well-known anti-inflammatory
phytoagent with also proved anti-fibrotic activity in liver disease [20,21]. Chlorogenic acid is the major
phenolic component of green coffee beans: the extract was showed to have antidiabetes, anti-lipidemic,
anti-obesity properties [22]. Vitamin E is a well-known antioxidant, tested for hepatic steatosis in
PIVEN trial with satisfying results [7] and, at present, could be given as therapy for NASH to selected
categories of patients.
AP-NHm was tested in vitro and in vivo. In vitro experiments were performed on the human
hepatocellular carcinoma cell line HepG2, which was treated with oleic acid: on this model of
steatosis [23–25] we tested the hepatoprotective effect of AP-NHm at three different increasing
concentrations (AP-NHm 1, AP-NHm 2, AP-NHm 3 in 1:3:10 ratio), both in co-treatment and
post-injury regimens. The nutraceutical mixture was concentration-dependently able to reduce the
complex metabolic damage induced by lipid load and, interestingly, the product was active both
in preventing alteration and in reducing the established damage. The in vivo studies tested the
beneficial effects of AP-NHm at two different increasing concentrations (1:3 ratio) in a mouse model
of NASH, induced by prolonged feeding with a high-fat diet (HFD, 60% fat), in two protocols of
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administrations: preventive (co-treatment) or therapeutic (post-injury). Protection was achieved in
a dose-dependent manner: an almost complete prevention was obtained at higher concentrations,
when daily administered from day one in co-treatment; a significative recovery was also evidenced in
rodents treated immediately after the onset of metabolic alterations.
2. Materials and Methods
2.1. Cell Culture and Steatosis Model
The steatosis model was reproduced in vitro using the human hepatocellular carcinoma cell line
HepG2. Cells were treated with 0.5-mM oleic acid (in 1% BSA; OA/BSA) for 24 h [23–25]. The cell
line HepG2 (hepatocellular carcinoma cell line) was obtained by American Type Culture Collection
(Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO
Life Technologies, Grand Island, NY, USA) with 10% (vol/vol) bovine fetal serum in the presence of 1%
antibiotic–antimycotic solution at 37 ◦C with 5% CO2. Confluent cells were treated with 0.5-mM oleic
acid in the presence of 1% albumin for 24 h. Control condition was performed allowing incubation
with albumin. The effect of 3 differently concentrated AP-NHm co-incubated with OA/BSA (24 h;
co-treatment protocol) or incubated for 48 h suddenly after 24 h treatment with OA/BSA (post-injury
protocol) was evaluated.
2.2. Animals
Male C57BL/6 mice (Envigo, Varese, Italy) weighing approximately 20 g at the beginning of the
experimental procedure were used. Animals were used in CeSAL (Centro Stabulazione Animali da
Laboratorio, University of Florence) and used at least one week after their arrival. Twelve mice were
housed per cage (size 26 × 41 cm) kept at 23.0 ± 1.0 ◦C with a 12 h light/dark cycle, with lights on
at 7 a.m.; during acclimatization they were fed a standard laboratory diet and tap water ad libitum.
All animal manipulations were carried out according to the Directive 2010/63/EU of the European
parliament and of the European Union council (22 September 2010) on the protection of animals used
for scientific purposes. The ethical policy of the University of Florence complies with the Guide for
the Care and Use of Laboratory Animals of the US National Institutes of Health (NIH Publication no.
85–23, revised 1996; University of Florence assurance number: A5278-01). Formal approval to conduct
the experiments described was obtained from the Animal Subjects Review Board of the University
of Florence. Experiments involving animals were reported according to ARRIVE guidelines [26].
All efforts were made to minimize animal suffering and to reduce the number of animals used.
2.3. Induction of Metabolic Syndrome
Metabolic syndrome was induced feeding the animals with a high-fat diet (HFD; Research Diets,
New Brunswick, NJ, USA) for 12 weeks ad libitum. The model is consistent, with minor modification,
to what was previously published [27,28]. HFD contains: 60% fat, 20% protein and 20% carbohydrate,
as a percentage of total Kcal [29]. Control animals were fed ad libitum for 12 weeks with a standard
diet (24% protein, 58% carbohydrate, 18% fat; Envigo, Varese, Italy).
2.4. Preparation of AP-NHm
The nutraceutical formulation AP-NHm based on vegetal extracts contains:
• pure omega 3 fatty acid (DHA) (Sochim International S.p.A., Cornaredo, Milan, Italy);
• pure choline bitartrate (Giusto Faravelli S.p.A., Milan, Italy);
• hydroalcoholic dry extract prepared by means of aqueous extraction and alcoholic precipitation
(30:70) from Tanacetum parthenium, characterized by 0.1% parthenolides (EPO S.r.l., Milan, Italy);
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• hydroalcoholic dry extract prepared by means of aqueous extraction and alcoholic precipitation
(50:50) from Silybum marianum, characterized by 80% silymarin (VIVATIS PHARMA Italia S.r.l.,
Varese, Italy);
• hydroalcoholic dry extract prepared by means of aqueous extraction and alcoholic precipitation
(50:50) from green coffee beans, characterized by 45% chlorogenic acid and 5% caffeine (VIVATIS
PHARMA Italia S.r.l., Varese, Italy);
• DL α-tocopheryl acetate: 7.5 µg/mL.
2.5. Treatments
In vitro experiments were carried on a model of steatosis reproduced on the human hepatocellular
carcinoma cell line HepG2 treated with 0.5 mM oleic acid (in 1% BSA; OA/BSA) for 24 h [23–25].
We evaluated the hepatoprotective effect of AP-NHm at 3 different growing concentrations (AP-NHm 1,
AP-NHm 2, AP-NHm 3 in 1:3:10 ratio) in two protocols: co-treatment (co-incubation with OA/BSA for
24 h) and therapeutic or post-injury (48 h of recovery incubation with AP-NHm immediately after 24 h
treatment with OA/BSA). AP-NHm 1, 2 and 3 presented the same proportion of components at different
concentrations as depicted in Table 1. In vivo, HFD-mice were divided into two arms: co-treatment
(treating simultaneously with HFD feeding) and post-injury (treating started with NASH onset).
In both cases, mice were treated with AP-NHm 1 or 2, low dose and high dose, respectively, differing in
concentration (1:3 ratio) as shown in Table 1. Mixtures were suspended in 1% carboxymethylcellulose
sodium salt and per os administered. The administration was divided in two parts: a morning treatment
(1 h after the light phase of the circadian light/dark cycle in the animal facility) and an evening treatment
(1 h before the dark phase), as explained by Supplementary Table S1.
Table 1. Concentration of components in multicomponent food supplement mixtures (AP-NHm): each
preparation for in vitro and in vivo experiments.
In Vitro Experiments
Component AP-NHm 1 (µg/mL) AP-NHm 2 (µg/mL) AP-NHm 3 (µg/mL)
DHA 1 3 10
Choline Bitartrate 1 3 10
Tanacetum parthenium Extract 5 15 50
Silybum marianum Extract 5 15 50
Green Coffee Beans Extract 5 15 50
dl α-tocopherol Acetate 0.75 2.5 7.5
In Vivo Experiments
Component AP-NHm 1 (µg/mL) AP-NHm 2 (µg/mL) AP-NHm 3 (µg/mL)
DHA 1 3 10
Choline Bitartrate 1 3 10
Tanacetum parthenium Extract 5 15 50
Silybum marianum Extract 5 15 50
Green Coffee Beans Extract 5 15 50
dl α-tocopherol Acetate 0.75 2.5 7.5
DHA: Docosahexaenoic acid.
2.6. Cell Viability (MTT)
Cell viability was evaluated by the reduction of 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) as an index of mitochondrial compartment functionality. Post treatments, after three
extensive washing, 1 mg/mL MTT was added into each well and incubated for 2 h at 37 ◦C.
After washing, the formazan crystals were dissolved in 100 µL dimethyl sulfoxide. The absorbance was
measured at 580 nm. Experiments were performed in quadruplicate on at least 3 different cell batches.
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2.7. Measurements of Superoxide Dismutase (SOD) Activity
Total SOD activity was determined by monitoring the inhibition of the reduction of ferricytochrome
C at 550 nm, using the xanthine–xanthine oxidase system as the source of superoxide. One unit of
the SOD is defined as the amount of the enzyme required to inhibit 50% of the rate of cytochrome-C
reduction [30]. Catalase activity was measured by following the rate of H2O2 consumption
spectrophotometrically at 240 nm.
2.8. Evaluation of Lipid Peroxidation in Cellular Model (Thiobarbituric Acid Reactive Substances, TBARS)
After treatments, cells were scraped, and cell suspension underwent a freeze/thaw cycle.
The suspension was added to 4 mL reaction mixture consisting of 36-mM thiobarbituric acid
(Sigma-Aldrich, Milano, Italy) solubilized in 10% CH3COOH, 0.2% SDS, pH was adjusted to 4.0 with
NaOH. The mixture was heated for 60 min at 100 ◦C and the reaction was stopped by placing the
vials in ice bath for 10 min. After centrifugation (at 1600× g at 4 ◦C for 10 min) the absorbance of the
supernatant was measured at 532 nm (PerkinElmer spectrometer, PerkinElmer, Waltham, MA, USA)
and TBARS were quantified in µmoles/milligram of total protein using 1,1,3,3-tetramethoxypropane
as standard.
2.9. Evaluation of Proinflammatory Cytokines
TNF-alfa and IL-8 were measured in the culture medium and in plasma by using a commercially
available enzyme-linked immunosorbent assay (BioSource, Bergamo, Italy).
2.10. Evaluation of Glucose Uptake
The cell uptake of 6-hydroxy glucose was measured via colorimetric reaction (Abcam,
Milano, Italy).
2.11. Evaluation of Steatosis Grade by Oil Red Staining
After treatments cells were fixed in 4% formaldehyde for 15 min, then washed in PBS and
incubated for 5 min with 60% isopropanol. Cells were treated with 0.1% oil red solution for 1 h.
After an additional wash images were captured under a light microscope and optical density (O.D.)
was measured.
2.12. Evaluation of Total Cholesterol and Triglycerides
After treatment, lipids were extracted from cells with chloroform: isopropanol: tween-20 solution
(7:11:0.1). Enzymatic methods applied to commercial kit were used to perform specific quantitative
measurements (BioSource, Italy).
2.13. Body Weight and Food Intake
During the experiment, the body weight of mice was measured every 3 days while the food intake
was measured weekly.
2.14. Collection of Blood and Analytical Methods
Blood was collected from the facial vein of the mice under light ether anesthesia into Eppendorf
tubes containing heparin (20 µL, 25,000 IU/5 mL) weekly starting from week 1. Samples were analyzed
for glucose, triglycerides and total cholesterol levels using a Reflotron reflectance photometric analyzer
(Reflotron, Roche Diagnostics, Monza, Italy). LDL and HDL cholesterol were measured using the same
method only on week 12 (Day 84).
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2.15. Glucose Tolerance Test
On week 12, glucose tolerance test was performed by intraperitoneally injections of glucose
(1 mg kg−1). Blood glucose was measured by Accu-Chek Aviva (Roche Diagnostics, Monza, Italy) at
0 min, 15 min and 30 min after glucose injections.
2.16. Tissues Explant
On week 12 (Day 84), after the behavioral measurements and the biochemical analysis, mice were
sacrificed by cervical dislocation and tissues explant was performed. In particular, perigonadal fat pad,
liver, heart and kidney were collected and weighted.
2.17. Liver Histopathology
Liver tissue samples were fixed in 4% formalin and processed for embedding and sectioning.
Liver sections (5 µm) were stained with hematoxylin and eosin (H&E). The quantitative scoring of
H&E-stain-based liver tissue sections was conducted according to the previous methods with slight
modifications, regarding steatosis [31,32]. Briefly, each section was examined by a specialist who was
blinded to the sample information and hepatic steatosis and inflammation scores were evaluated.
The degree of steatosis was graded ‘0’ to ‘10’ based on the average percent of fat-accumulated hepatocyte
per field at 4 or 20× magnification under H&E staining (grading 0, <5% of fat accumulation and
grading 10, >75% of fat accumulation).
2.18. Lipid Levels in Liver
Liver homogenate was dosed for triglycerides, LDL and HDL cholesterol using a Reflotron
reflectance photometric analyzer (Reflotron, Roche Diagnostics, Monza, Italy).
2.19. Adipose Tissue Histopathology
The perigonadal fat pad was collected for histological and biochemical analyses. For histology,
the tissues were drop-fixed in 10% neutral buffered formalin for 2–3 days, after which they were
processed for paraffin embedding. Five-micrometer sections were then cut, collected, stained with
hematoxylin and eosin and digitized. Adipocyte size was measured by an investigator blinded to the
experimental grouping in × 40 microscope fields by counting the total number of adipocytes within
predefined area grids and then dividing the area by the total number of adipocytes within the grids
to calculate average adipocyte size. For each sample, three replicate tissue sections were analyzed,
with three fields counted in each section, for a total of nine fields averaged per sample.
2.20. Evaluation of Lipid Peroxidation in Tissue (Thiobarbituric Acid Reactive Substances, TBARS)
Thiobarbituric acid-reactive substances (TBARS) assay was assessed as an index of lipid
peroxidation according to [33]. The TBARS determination was carried out in mice liver and heart
homogenate obtained from tissue homogenized in PBS at the final concentration of 10% w/v. Then were
added FeCl3 (20 µM, Sigma-Aldrich, St. Louis, MO, USA) and ascorbic acid (100 µM, Sigma-Aldrich) to
obtain the Fenton reaction. At the end of incubation, the mixture was added to 4 mL reaction mixture
consisting of 36-mM thiobarbituric acid (Sigma-Aldrich) solubilized in 10% CH3COOH, 0.2% SDS,
and pH was adjusted to 4.0 with NaOH. The mixture was heated for 60 min at 100 ◦C and the reaction
was stopped by placing the vials in an ice bath for 10 min. After centrifugation (at 1600 g at 4 ◦C for
10 min) the absorbance of the supernatant was measured at 532 nm (PerkinElmer spectrometer) at
550 nm (PerkinElmer spectrometer) and TBARS were quantified in µmol/mg of total proteins using
1,1,3,3-tetramethoxypropane as the standard.
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2.21. Carbonylated Proteins
Carbonylated proteins were evaluated in liver and heart tissue homogenate. Tissue proteins
extract was quantified by BCA. Twenty micrograms of each sample were denatured by 6% SDS and
derivatized by 15-min incubation with 2–4 dinitrophenyl hydrazine (DNPH; Sigma-Aldrich, Italy) at
room temperature. Samples were separated on a 4–12% sodium dodecyl sulfate (SDS)-polyacrylamide
gel by electrophoresis and transferred onto nitrocellulose membranes (BioRad, Italy). Membranes
were blocked with 5% nonfat dry milk in phosphate-buffered saline (PBS) containing 0.1% Tween-20
(PBST) and then probed overnight with primary antibody specific versus DNPH (Sigma-Aldrich, Italy)
1:5000 in PBST/5% nonfat dry milk. After washing with PBST, the membranes were incubated for 1 h
in PBST containing the appropriate horseradish peroxidase-conjugated secondary antibody (1:5000;
Cell Signaling, Danvers, MA, USA) and again washed. ECL (Pierce, USA) was used to visualize
the peroxidase-coated bands. Densitometric analysis was performed using the “ImageJ 1.42” image
analysis software (NIH, Bethesda, ML, USA). For each experiment, the density of all bands showed in
a lane was reported as mean. The total protein amount quantified by Ponceau staining was used to
normalize all samples.
2.22. Statistical Analysis
Each in vitro experiment was performed at least three times. In vivo measurements were
performed on 12 animals for each group, analyzed in 2 different experimental arms (co-treatment and
post-injury) by researchers blinded to the treatment procedure. Results were expressed as means ±
SEM and the analysis of variance was performed by ANOVA test. A Bonferroni’s significant difference
procedure was used as a post hoc comparison. p-values less than 0.05 were considered significant.
Data were analyzed using the “Origin 8.1” software (Northampton, MA, USA).
3. Results
3.1. In Vitro Experiments
3.1.1. AP-NHm Protects Cellular Proliferative Abilities
Human hepatocellular carcinoma cell viability and proliferation were tested in both co-treatment
and post-injury protocols. Incubation of HepG2 cells for 24 h with OA/BSA did not significantly modify
cell viability (Figure 1a), while it negatively influenced cellular proliferative activity, since it decreased
by one third compared to control cells. In post-injury protocol, treatment with AP-NHm 2 and 3 for
48 h almost completely restored the proliferative capabilities (Figure 1b).
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Figure 1. Effects of oleic acid (OA) and AP-NHm on epG2: cell viability (a) and cellular proliferation
(b). HepG2 were incubated with 0.5-mM oleic acid (OA) in 1% bovine serum albumin (BSA) (OA/BSA)
or BSA alone for 24 h in co-treatment or in post-injury recovery treatment (48 h) with AP-NHm 1, 2, 3.
** p< 0.01 vs. BSA + vehicle; ˆ p < 0.05 vs. OA/BSA + vehicle.
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3.1.2. AP-NHm Restores Mitochondrial SOD Activity and Ameliorated Lipid Peroxidation Status
OA/BSA treatment altered oxidative stress defense system and redox balance, as showed by
mitochondrial superoxide dismutase (SOD) activity and lipid peroxidation status (Figure 2a–d).
Lipid overloading reduced antioxidant properties of mitochondria since activity of SOD was almost
halved after 24 h of incubation. In the preventive co-treatment protocol, harm was significantly
attenuated by AP-NHm 1 and even totally canceled by AP-NHm 2 and 3 (Figure 2a); nevertheless,
only AP-NHm 2 and 3 were able to re-activate mitochondrial enzyme at the end of the 48 h treatment
following the insult (Figure 2b). Treatment with OA/BSA induced an increase of TBARS (thiobarbituric
acid reactive substances) 24 h after treatment and after 48 h of recovery. One-day co-incubation with the
three AP-NHm doses induced a significant decrease in TBARS in a dose-dependent manner (Figure 2c).
The repairing effect was instead less intense after the two-day incubation with AP-NHm 3 and totally
absent in the treatment with AP-NHm 1 and 2 (Figure 2d).
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(a) and post-injury (b) regimens; lipid peroxidation in co-treatment (c) and post-injury (d) regimens.
HepG2 were incubated with 0.5-mM oleic acid in 1% BSA(OA/BSA) or BSA alone for 24 h in co-treatment
or in post-injury recovery treatment (48 h) with AP-NHm 1, 2, 3. * p < 0.05 and ** p < . 1 vs. BSA +
vehicle, ˆ p < 0.05 and ˆˆ p < 0.01 vs. OA/BSA + vehicle.
3.1.3. AP-NHm Obstacles Inflammatory Events
Inflammatory events were assessed by measuring TNF-α and interleukin-8 (IL-8) in the culture
medium. A high inflammation state caused by lipid overloading for 24 h as sho ed by elevated
cytokines levels in both protoc ls, even if a weak decrease of inflammation occurred 2 ays fter the end
of th insulting treatment. Preventiv co-incubation and post-injury recovery incubation of 48 h with
the supplementary ixture AP-NHm reduced TNF-α and IL 8 levels in a concentr tion-dependent
mann r (Table 2). Th highest concentration of components (AP-NHm 3) almost halved the pat ologic
levels of cyt kines in both regimen .
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Table 2. Effects of OA and AP-NHm mixture on TNF-α and IL-8 concentration (pg/mL) in the
cellular medium.
(pg/mL) BSA + Vehicle OA/BSA AP-NHm 1 AP-NHm 2 AP-NHm 3
Co-treatment
TNF-α 24.3 ± 2.4 94.8 ± 7.4 ** 85.1 ± 5.6 60.4 ± 4.9 ˆˆ 54.9 ± 7.2 ˆˆ
IL-8 12.6 ± 0.9 144.4 ± 10.3 ** 112.3 ± 7.8 ˆ 80.6 ± 6.4 ˆˆ 62.1 ± 8.6 ˆˆ
Post-injury TNF-α 20.5 ± 1.6 65.3 ± 3.6 ** 68.3 ± 5.5 48.1 ± 3.6 ˆ 40.9 ± 2.2 ˆˆ
IL-8 18.3 ± 2.0 96.3 ± 8.4 ** 96.1 ± 3.4 50.4 ± 4.2 ˆˆ 49.3 ± 5.6 ˆ
OA: oleic acid; BSA: bovine serum albumin; ** p < 0.01 vs. BSA + vehicle, ˆ p < 0.05 vs. OA/BSA + vehicle, ˆˆ p < 0.01
vs. OA/BSA + vehicle.
3.1.4. AP-NHm has Protective Effects on Metabolic Alteration
We investigated the protective abilities of the three doses of AP-NHm in the most relevant
signatures of metabolic syndrome: alteration of glucides, triglycerides and cholesterol. Carbohydrate
metabolism was tested through cell glucose uptake after insulin stimulation of 1-µM (Table 3).
Following OA/BSA incubation, insulin sensitivity was significantly reduced (40% less after 1 day).
In the post-injury treatment insulin sensitivity was 70% less at the end of the recovery time, free from
lipid solution. The administration of AP-NHm exhibited a concentration-dependent rescuing effect,
reaching an almost complete recovery with the third composition.
Table 3. Effects of OA and AP-NHm mixture on glucose uptake following stimulation with 1-µM insulin.
BSA + Vehicle OA/BSA AP-NHm 1 AP-NHm 2 AP-NHm 3
Co-treatment
Control 6.4 ± 0.6 5.6 ± 0.6 9.8 ± 2.1 5.4 ± 0.6 6.4 ± 3.6
Insulin 1 µM 128.6 ± 4.3 76.2 ± 4.8 ** 97.6 ± 6.7 ˆ 107.4 ± 6.8 ˆˆ 110.9 ± 8.7 ˆˆ
Post-injury Control 4.6 ± 1.2 8.8 ± 3.7 3.9 ± 0.9 6.4 ± 2.1 5.4 ± 2.3
Insulin 1 µM 139.2 ± 10.3 42.6 ± 5.9 ** 40.6 ± 14.6 79.1 ± 7.4 ˆˆ 109.8 ± 12.3 ˆˆ
** p < 0.01 vs. BSA + vehicle, ˆ p < 0.05 vs. OA/BSA + vehicle, ˆˆ p < 0.01 vs. OA/BSA + vehicle.
3.1.5. AP-NHm Reduces and Impairs Intracellular Lipid Deposits
Intracellular triglycerides and cholesterol deposits were enlarged by treatment with the
combination of OA/BSA, an effect that was observed by analyzing cellular triglycerides/protein
(Figure 3a,b) and cholesterol/protein (Figure 3c,d) ratio. Following incubation with OA/BSA,
triglycerides/protein ratio was about four times higher than the control group. Co-incubation
(Figure 3a) and post-injury-incubation (Figure 3b) with AP-NHm produced different effects: during the
co-incubation only AP-NHm 3 was able to reduce lipid presence; in the post-injury treatment of 48 h
AP-NHm 2 and 3 reduced the lipid deposits in a concentration-dependent manner, since the latter almost
halved the ratio. Lipid overload increased the concentration of total cholesterol (Figure 3c,d), but in
both treatment protocols a protective effect of AP-NHm 2 and 3 was found. Indeed, the co-incubation
with AP-NHm 2 and 3 lowered the cholesterol levels to normal values (Figure 3c) in preventive
experiments. In post-treatment (Figure 3d), at the end of the 48-hour recovery, the cholesterol levels
decreased in a concentration-dependent manner in all three treatment groups.
3.1.6. AP-NHm Improves Steatosis Grade
Oil Red staining of cells highlighted lipid accumulation, pointing to the respective steatosis
grade shown as optical density (O.D.) analysis (Figure 4a,b). OA/BSA treatment strongly increased
the steatosis grade of cells, but the damage was widely reduced by co-treatment with AP-NHm 3
(Figure 4a) and by post-injury incubation with AP-NHm 2 and 3 (Figure 4b).
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Figure 4. Effects of AP-NHm 3 on steatosis grade easured by oil red staining. HepG2 were incubated
with 0.5-mM oleic acid in 1% BSA (OA/BSA) or BSA alone for 24 h in co-treatment or in post-injury
recovery treatment (48 h) with AP-NHm 1, 2, 3. (a) optical density (OD) of lipid accumulation with
AP-NHm in co-treatment regimen; (b) OD of lipid accumulation with AP-NHm in post-injury regimen.
** p < 0.01 vs. BSA + vehicle, ˆˆ p < 0.01 vs. OA/BSA + vehicle.
3.2. In Vivo Experiments
3.2.1. AP-NHm 2 Co-Tr atment Results in Weight Loss
Animals were fed for 12 weeks a libitum with ither s andard diet or high-fat diet and first
signs of metabolic disorders appeared after 6–7 weeks of HFD: in those mice, on Day 42 the blood
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levels of total cholesterol, triglycerides and glucose were significatively increased with respect to
the standard diet fed animals (Supplementary Table S2). Following the protocols used for in vitro
experiments, two protocols were scheduled also for in vivo treatments: a co-treatment with two
different concentrations of AP-NHm, administered simultaneously with HFD feeding from week
1 to week 12 (Day 1 to Day 84), and a post-injury treatment, beginning on week 7 (on Day 49),
once hepatosteatosis was established, as confirmd by metabolic alterations. Control groups of both
diets (standard and fat-rich) were treated with vehicle (1% carboxymethyl cellulose sodium salt).
Body weight of rodents from each experimental group were monitored for the duration of the study
(Figure 5a): HFD-fed animals showed a significant weight increase starting from Day 30; the HFD
group co-treated with AP-NHm 2 exhibited a loss of body weight from Day 41; the same concentration
of nutrients induced a remarkable reduction of body weight from Day 66 to 78 in the post-injury
protocol. The AP-NHm 1, in both protocols, was ineffective on this parameter. The evaluation of food
intake showed that high-fat diet determined its reduction with no influence from the supplementation
with AP NHm (Figure 5b).Nutrients 2020, 12, x FOR PEER REVIEW 12 of 26 
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3.2.2. AP-NHm has Hypocholesterolemic, Hypolipidemic and Hypoglycemic Effects 
Blood levels of total cholesterol, triglycerides and glucose were measured every week to monitor 
the typical metabolic alterations of this disease model that, starting from Day 42, showed a significant 
increase in comparison to normal diet-fed group, thus leading to set the beginning of the post-injury 
treatment on Day 49, i.e., when hepatosteatosis syndrome was firmly settled. In Table 4 the effects of 
both AP-NHm mixtures in the co-treatment and post-injury protocols (in table marked as groups 3–
Figure 5. Effects of high-fat diet (HFD) and AP-NHm 1–2, in co-treatment or in post-injury treatment,
(a) on body weight fr m ay 0 and (b) n food intake from Day 42 to Day 84. Mice were fed with
normal or HFD diet from Day 0 to Day 84: two groups were co-treated with AP-NHm while other two
groups started AP-NHm reatment on Day 49. Control groups were treated with vehicle throughout
the study. Each value represents the mean ± SEM of 12 mice per group. ** p < 0.01 vs. standard diet +
vehicle, ˆˆ p < 0.01 vs. HFD + vehicle.
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3.2.2. AP-NHm has Hypocholesterolemic, Hypolipidemic and Hypoglycemic Effects
Blood levels of total cholesterol, triglycerides and glucose were measured every week to monitor
the typical metabolic alterations of this disease model that, starting from Day 42, showed a significant
increase in comparison to normal diet-fed group, thus leading to set the beginning of the post-injury
treatment on Day 49, i.e., when hepatosteatosis syndrome was firmly settled. In Table 4 the effects of
both AP-NHm mixtures in the co-treatment and post-injury protocols (in table marked as groups 3–4
and 5–6, respectively) were reported till Day 84. In co-treatment AP-NHm 2 was able to fully normalize
total cholesterol over the 6 weeks and to restore LDL levels on Day 84, while HDL was higher than
control levels; AP-NHm 1 had an hypocholesterolemic activity on days 70 and 77. Post-injury regimen
was effective with only AP-NHm 1 starting from Day 70 until Day 84 and on the last day also LDL
appeared ameliorated, whereas HDL was unchanged. A similar trend was observed for triglyceride
blood levels whose oscillations were due to the different treatment modalities and dose of mixture
supplemented to the animals. Co-treatment with both AP–NH mixtures was effective from Day 49
till the end of the experiment, but more striking results emerged in the group treated with high-dose
AP-NHm; post-injury administrations significantly reduced lipid levels from Day 70 with AP-NHm 2,
from Day 77 with AP-NHm 1. Hyperglycemia was not totally abolished by supplementations, but it
was diminished: simultaneous administration of AP-NHm 2 with fat-rich diet caused an about 20%
reduction from Day 49 till the end of the study, while in post-injury protocol the same AP-NHm 2 was
effective from Day 70; AP-NHm 1 did not induce any amelioration. Similar results were observed in
metabolism response to glucose load, via oral glucose tolerance test: HFD feeding altered metabolism
ability to catch glucose, since an increasing hyperglycemia was set following glucose administration.
As in hyperglycemia test, supplementation with AP-NHm 1 was ineffective, while co-treatment with
AP-NHm 2 showed beneficial results also in post-injury protocol, even if with lesser extent results.
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Table 4. Hematic parameters throughout the study: values of cholesterol, triglyceride and glucose from Day 47–Day 84; glucose tolerance test on Day 84. Group 1:
standard diet + vehicle; group 2: HFD + vehicle; group 3: HFD + AP-NHm 1 co-treatment; group 4: HFD + AP-NHm 2 co-treatment; group 5: HFD + AP-NHm 1
post-injury; group 6: HFD + AP-NHm 2 post-injury.
Hematic total cholesterol (mg/dL) Hematic HDL(mg/dL)
Hematic LDL
(mg/dL)
Group Day 49 Day 56 Day 63 Day 70 Day 77 Day 84 Day 84 Day 84
1 102.6 ± 5.1 105.0 ± 5.0 107.0 ± 1.2 105.3 ± 0.9 102.6 ± 2.1 103.8 ± 4.1 51.8 ± 8.5 43.8 ± 6.7
2 140.7 ± 3.4 ** 145.8 ± 3.8 ** 149.9 ± 2.6 ** 155.3 ± 4.8 ** 153.8 ± 5.3 ** 160.6 ± 3.5 ** 60.3 ± 7.0 73.8 ± 5.2 **
3 135.6 ± 4.9 142.8 ± 5.1 145.3 ± 3.7 144.2 ± 4.6 ˆ 143.1 ± 3.1 ˆ 150.6 ± 6.8 62.2 ± 5.2 70.6 ± 3.3
4 103.3 ± 3.2 ˆˆ 104.0 ± 4.3 ˆˆ 113.0 ± 5.4 ˆˆ 120.0 ± 6.2 ˆˆ 125.0 ± 4.8 ˆˆ 129.1 ± 4.6 ˆˆ 73.4 ± 2.3 ˆ 36.9 ± 6.3 ˆˆ
5 142.5 ± 6.2 146.4 ± 6.2 147.3 ± 6.5 145.1 ± 8,3 150.3 ± 4.1 156.9 ± 8.6 59.1 ± 10.5 46.0 ± 9.4 ˆˆ
6 141.9 ± 6.1 144.9 ± 5.3 143.8 ± 3.3 144.1 ± 4.1 ˆ 142.8 ± 3.2 ˆ 140.1 ± 5.4 ˆˆ 62.9 ± 4.9 53.2 ± 4.0 ˆˆ
Triglyceride hematic levels (mg/dL)
Group Day 49 Day 56 Day 63 Day 70 Day 77 Day 84
1 69.0 ± 6.9 71.6 ± 4.4 72.3 ± 6.4 70.5 ± 3.8 69.9 ± 6.1 72.9 ± 5.2
2 142.3 ± 4.3** 145.7 ± 6.2 ** 146.3 ± 4.8 ** 151.2 ± 2.2 ** 154.4 ± 5.0 ** 159.3 ± 7.7 **
3 115.6 ± 4.3ˆ 114.1 ± 6.6 ˆ 109.0 ± 5.7 ˆˆ 115.5 ± 3.1 ˆ 105.6 ± 4.3 ˆ 100 ± 5.8 ˆˆ
4 85.8 ± 5.0ˆ 84.2 ± 6.4 ˆ 86.5 ± 10.7 ˆ 90.4 ± 7.8 ˆˆ 89.5 ± 5.1 ˆˆ 92.7 ± 5.3 ˆˆ
5 145.4 ± 7.6 147.1 ± 9.5 143.7 ± 6.7 140.8 ± 6.1 141.2 ± 3.6 ˆ 139.8 ± 4.4 ˆˆ
6 142.0 ± 9.0 145.7 ± 5.5 140.9 ± 6.4 130.1 ± 3.2 ˆ 128.6 ± 5.0 ˆˆ 129.2 ± 3.0 ˆˆ
Hematic glucose (mg/dL)
Group Day 49 Day 56 Day 63 Day 70 Day 77 Day 84
1 103.0 ± 2.9 105.7 ± 4.4 101.3 ± 10.1 103.3 ± 4.4 99.6 ± 6.1 105.3 ± 4.6
2 160.5 ± 6.9 ** 155.4 ± 4.2 ** 158.3 ± 3.9 ** 162.5 ± 6.1 ** 164.4 ± 5.1 ** 168.3 ± 9.4 **
3 160.6 ± 8.0 158.3 ± 6.1 163.5 ± 10.7 161.5 ± 5.1 155.0 ± 2.8 166.7 ± 6.5
4 123.0 ± 5.1ˆ 120.4 ± 5.5 ˆ 123.9 ± 2.0 ˆ 133.8 ± 6.0 ˆ 139.4 ± 6.1 ˆ 145.9 ± 6.4 ˆ
5 152.0 ± 9.9 158.3 ± 6.5 163.3 ± 5.4 159.6 ± 5.9 161.2 ± 8.8 156.3 ± 5.7
6 153.0 ± 6.2 158.5 ± 8.1 154.8 ± 7.1 146.3 ± 5.5 ˆ 144.4 ± 3.9 ˆ 143.8 ± 4.0 ˆ
Glucose tolerance test (Day 84): hematic glucose (mg/mL)
Group Pretest 15 min 30 min
1 105.3 ± 4.6 161.7 ± 3.2 189.0 ± 9.0
2 168.3 ± 9.4 ** 267.0 ± 6.7 ** 305.0 ± 5.9 **
3 166.7 ± 6.5 264.3 ± 8.5 291.2 ± 6.2
4 145.9 ± 6.4 ˆ 182.4 ± 9.0 ˆ 221.8 ± 11.4 ˆ
5 156.3 ± 5.7 263.7 ± 10.2 294.7 ± 9.9
6 143.8 ± 4.0 ˆ 220.8 ± 10.1 ˆ 259.1 ± 11.6 ˆ
Each value represents the mean ± SEM of 12 mice per group. ** p < 0.01 vs standard diet + vehicle, ˆ p < 0.05 vs HFD + vehicle, ˆˆ p < 0.01 vs HFD + vehicle. HFD: high-fat diet.
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3.2.3. AP-NHm has Anti-Inflammatory Effects
At the end of the study, blood samples were collected from all groups and two cytokines were
titrated: TNF-α and IL-8 (Table 5). Both molecules resulted more concentrated in blood of HFD-fed
rodents than control hematic samples. Co-treatment protocol with both AP-NHm mixtures was able to
prevent an excessive cytokine concentration increase, even though the high-dose AP-NHm worked
better; post-injury treatment produced the same effect when dosed as AP-NHm 2.
Table 5. Effects of HFD and AP-NHm mixture on TNF-α and IL-8 blood concentration on Day 84.
Group 1: standard diet + vehicle; group 2: HFD + vehicle; group 3: HFD + AP-NHm 1 co-treatment;
group 4: HFD + AP-NHm 2 co-treatment; group 5: HFD + AP-NHm 1 post-injury; group 6: HFD +
AP-NHm 2 post-injury.
Group TNF-α (pg/mL) IL-8 (pg/mL)
Day 84
1 86.4 ± 6.7 249.6 ± 15.9
2 214.8 ± 12.6 ** 1087.6 ± 36.3 **
3 164.6 ± 9.5 ˆ 785.6 ± 40.5 ˆ
4 120.5 ± 7.5 ˆˆ 405.9 ± 26.8 ˆˆ
5 223.6 ± 16.8 987.9 ± 45.9
6 176.4 ± 6.1 ˆ 588.7 ± 28.5 ˆˆ
Each value represents the mean ± SEM of 12 mice per group. ** p < 0.01 vs standard diet + vehicle, ˆ p < 0.05 vs.
HFD + vehicle, ˆˆ p < 0.01 vs. HFD + vehicle.
3.2.4. AP-NHm Reduces Abnormal Heart, Liver and Adipose Tissue Weight
All the rodents were sacrificed and ex-vivo analysis was performed. The weight of the liver,
heart, kidney, and perigonadal fat pad, organs that underwent to the fat-rich diet-dependent
metabolic disorders were recorded (Figure 6a–d). Kidney weight was not affected neither by HFD
feeding, nor by supplementations, while significant changes in the weight of the other organs were
evidenced. Liver weight was dramatically increased (about 1000 mg) by HFD feeding, and the two
supplementation formulas prevented this hepatic fattening. In both regimens AP-NHm 2 was the
most effective, because its administration from the study onset completely prevent weight gain and
the therapeutic treating cut down liver mass increase; however, AP-NHm 1 was poor active and
only when administrated concomitantly to the fat-rich diet. The mass of the heart grew of 50% and
only co-treatment with high-dose AP-NHm 2 was able to counteract this pathologic effect. Under
fat-rich diet, also perigonadal fat weight, doubled (normalized to body weight) and this alteration was
attenuated only by administrating AP-NHm 2 in co-treatment regimen.
3.2.5. High dose AP-NHm Significantly Resizes Adipocyte Area of Perigonadal Fat Pad
Subsequent histological analysis focused on perigonadal adipose tissue and liver. Histological
sections of perigonadal adipose tissue (Figure 7a–f) and adipocyte area quantification (Figure 7g)
showed a HFD-dependent enlargement of adipocytes. This effect was significantly counteracted by
AP-NHm 2 in both treatments.
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** p < 0.01 vs. standard diet + vehicle, ˆ p < 0.05 and ˆˆ p < 0.01 vs. HFD + vehicle.Nutrients 2020, 12, x FOR PEER REVIEW 23 of 26 
 
Figure 7. Effects of AP-NHm 1–2, in co-treatment or in post-injury treatment, on adipose tissue and 
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treatment, (e) HFD + AP-NHm 1 post-injury, (f) HFD + AP-NHm 2 post-injury; (g) area of adipocytes 
(µm2) in each group of treatment. Each value represents the mean ± SEM of 12 mice per group. ** p < 
0.01 vs. standard diet + vehicle, ^^ p < 0.01 vs. HFD + vehicle. 
3.2.6. AP-NHm Protects from Hepatic Fat-Accumulation 
Under hematoxylin and eosin staining (Figure 8a–f) the hepatic tissue appeared strongly 
steatotic in the fat-rich diet group; indeed, in a steatosis index ranging from 0 to 10 scale, where 0 
states for <5% and “10” for >75% of fat-accumulated hepatocytes, the hepatic tissue scores “8” 
steatosis grade per field (Figure 8g). AP-NHm 2 was protective from fat-accumulation at both 
regimens, although more effective in co-administration, whereas AP-NHm 1 was effective only in co-
treatment with the diet. 
Figure 7. Effects of AP-NHm 1–2, in co-treat r in post-injury treatme t, on adipose tissue and
adipocyte area of perigonadal fat pad. (a–f) Histology of tissue sections of adipose tissue: (a) standard
diet + vehicle, (b) HFD + vehicle, (c) HFD + AP-NHm 1 co-treatment, (d) HFD + AP-NHm 2 co-treatment,
(e) HFD + AP-NHm 1 post-injury, (f) HFD + AP-NHm 2 post-injury; (g) area of adipocytes (µm2) in
each group of treatment. Each value represents the mean ± SEM of 12 mice per group. ** p < 0.01 vs.
standard diet + vehicle, ˆ p < 0.01 vs. HFD + vehicle.
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3.2.6. AP-NHm Protects from Hepatic Fat-Accumulation
Under hematoxylin and eosin staining (Figure 8a–f) the hepatic tissue appeared strongly steatotic
in the fat-rich diet group; indeed, in a steatosis index ranging from 0 to 10 scale, where 0 states for <5%
and “10” for >75% of fat-accumulated hepatocytes, the hepatic tissue scores “8” steatosis grade per
field (Figure 8g). AP-NHm 2 was protective from fat-accumulation at both regimens, although more
effective in co-administration, whereas AP-NHm 1 was effective only in co-treatment with the diet.Nutrients 2020, 12, x FOR PEER REVIEW 24 of 26 
 
Figure 8. Effects of AP-NHm 1–2, in co-treatment or in post-injury treatment, on hepatic tissue and 
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+ vehicle, (c) HFD + AP-NHm 1 co-treatment, (d) HFD + AP-NHm 2 co-treatment, (e) HFD + AP-NHm 
1 post-injury, (f) HFD + AP-NHm 2 post-injury; (g) steatosis index of each group of treatment. Each 
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5 27.10 ± 3.29 28.56 ± 4.57 571.34 ± 101.56 
6 17.78 ± 1.01 ^ 20.03 ± 0.56 ^ 359.12 ± 41.34 ^ 
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3.2.7. AP-NHm Exerts an Antioxidant Effect on Heart and Liver 
Oxidative damage was verified in liver and heart assessing lipid peroxidation and protein 
carbonylation. In the heart HFD-dependent lipid peroxidation was buffered in post-treatment 
protocol by both supplementations with AP-NHm (Figure 9a); carbonylation of protein increased of 
Figure 8. Effects of AP-NHm 1–2, in co-treatment or in post-injury treatment, on hepatic tissue and
steatosis index. (a–f) Histology of tissue sections of hepatic tissue: (a) st ndard diet + vehicle, (b) HFD +
vehicle, (c) HFD + AP-N m 1 co-treatment, (d) HFD + AP-NHm 2 co-treatment, (e) HFD + AP-NHm 1
post-injury, (f) HFD + AP-NH 2 post-injury; (g) steatosis index of each group of treatment. Each value
represents the mean ± SEM of 12 mice per group. ** p < 0.01 vs. standard diet + vehicle, ˆ p < 0.05 and
ˆˆ p < 0.01 vs. HFD + vehicle.
HFD-diet affects the lipid concentration in hepatic parenchyma homogenate by increasing the
LDL and HDL concentration by 5 times and the triglyceride one by 6 times (Table 6). The AP-NHm
2 co-treatment and post-injury protocol were effective on all parameters, whereas the co-treatment
AP-NHm 1 protocol was effective only on HDL and triglycerides.
Table 6. Effects of HFD and AP-NHm mixture on l terol and triglyceride co centrations in liver
homogenat on Day 84.
Liver Homogenate Levels Dosages (Day 84)
Group LDL (mg/dL) HDL (mg/dL) Triglyceride (mg/dL)
1 5.10 ± 0.63 5.42 ± 0.51 93.12 ± 30.34
2 26.16 ± 3.12 ** 29.20 ± 3.61 ** 602.46 ± 89.32 **
3 21.40 ± 2.34 19.23 ± 1.32 ˆ 346.67 ± 39.12 ˆ
4 13.08 ± 1.21 ˆˆ 14.56 ± 2.12 ˆ 251.70 ± 29.54 ˆˆ
5 27.10 ± 3.29 28.56 ± 4.57 571.34 ± 101.56
6 17.78 ± 1.01 ˆ 20.03 ± 0.56 ˆ 359.12 ± 41.34 ˆ
Each value represents the mean ± SEM of 12 mice per group. ** p < 0.01 vs standard diet + vehicle, ˆ p < 0.05 vs.
HFD + vehicle, ˆˆ p < 0.01 vs. HFD + vehicle.
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3.2.7. AP-NHm Exerts an Antioxidant Effect on Heart and Liver
Oxidative damage was verified in liver and heart assessing lipid peroxidation and protein
carbonylation. In the heart HFD-dependent lipid peroxidation was buffered in post-treatment protocol
by both supplementations with AP-NHm (Figure 9a); carbonylation of protein increased of 40%, but it
was almost totally restored by both AP-NHm therapeutic administrations (Figure 9b,c). In the liver the
fat-rich diet led to significant lipid oxidation (Figure 9d). This oxidation was considerably diminished
by AP-NHm 2 in co-treatment with the feeding; whereas the percentage of carbonylated proteins were
reduced in co-treatment regimen by mix 1 and strongly reduced by mix 2. In post-injury treatment
only AP-NHm 2 exhibited a slight effect (Figure 9e,f).
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4. Discussion
In the present framework of research, we investigated the therapeutic and preventive effects of a
new nutraceutical multicomponent formulation (AP-NHm) on NASH in in vitro and in vivo models.
NASH is a liver pathology, the negative and more aggressive evolution of NAFLD, originally caused
by lipid accumula ion in he hepatocytes [4]. The diffusion of NASH is dramatic lly incr asing and in
the next years it is claimed to be t e first cause of HCC and liver transpl ntati n, therefore it represents
a worldwide health issue [2]. Nowadays, there is no pharmacological management accepted by FDA
and EMA and the first line of treatment is nutritional intervention, by changing lifestyle of patients.
According to EASL [34], AASL [35] and KASL [36], current medications could be vitamin E and the
PPAR–agonist pioglitazone, an insulin sensitizer in use for type 2 diabetes treatment, but only in
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selected categories of patients due to limiting side-effects, related to higher cancer risks, increased body
weight and not univocal results [6–10]. Many other promising drugs are in the pipeline or under clinical
trials [11,37], such as the FXR agonist OCA, which improved hepatic histology and induced fibrosis
remission of NASH patients in both phase 2 and phase 3 randomized controlled trials with the adverse
effect of a worsened cholesterol profile [12,13] and PPAR-α/δ agonist elafibranor, which showed an
ameliorating trend of pathologic parameters in subgroups of severe NASH patients [14]. In the field of
nutraceutical research many efforts are being made to delineate curative abilities of food bioactive
molecules and some nutrients were proved to possess ameliorative properties in metabolic disorders.
These are the qualities of those nutraceutical compounds present in AP-NHm as part of extracts or as
single molecules: silymarin, docosahexaenoic acid (DHA), choline, parthenolide, chlorogenic acid,
dl-α-tocopheryl acetate (vitamin E).
In the pathogenesis of NASH, mitochondrial dysfunction is a consequence of lipotoxicity and
in turn causes bad functioning of defensive mechanisms against oxidative stress [4]. Lipid load
of hepatocytes reduced superoxide dismutase (SOD) activity and increased lipid peroxidation
levels, but co-treatment with AP-NHm restored SOD activity and lowered TBARS levels in a
concentration-dependent manner, while the treatment after insult was able to ameliorate the oxidative
stress state only when dosed at the highest concentration. In mice, HFD feeding altered redox balance,
as showed by elevated levels of lipid peroxidation and carbonylated proteins in liver and heart.
High dose AP-NHm 2 was effective at improving oxidative unbalance both in preventive co-treatment
and in post-injury protocol, while the less concentrated AP-NHm 1 was able to counteract oxidation
mechanism only in co-treatment with HFD feeding. Several works supported the antioxidant activity
of the bioactive nutrients contained in AP-NHm. Stellavato et al. treated hepatic cells with a less rich
formulation and claimed the good antioxidant property of tocopherol acetate, DHA and silymarin [38];
tocopherol acetate is a well-known antioxidant [39], whose hepatoprotective effects proved in PIVEN
clinical trial were achieved at 800 IU/day, a much higher concentrations than dosage in AP-NHm
mixture [7]. Tanacetum parthenium extract probably did not participate in balancing the altered oxidative
equation, because many studies reported the ability of parthenolides to induce apoptosis via oxidative
stress, depleting GSH levels and rising intracellular ROS levels [21,40]. Silymarin and chlorogenic acid
contributed to enhance antioxidant competence of the cells, as verified also in other cases [41,42].
Lipotoxicity is also at the basis of inflammatory context in which hepatosteatosis established:
it sublethally injures hepatic cells and, as a result, proinflammatory cytokines are released. They recruit
hepatic immune cells and macrophages which infiltrate hepatic parenchyma and, in turn, exacerbate
the inflammatory response, turning it from acute to chronic. In our study, the extremely high levels of
the two inflammatory cytokines TNF- and IL-8 in cellular medium and in the blood of rodents revealed
the activation of the inflammatory cascade. Their presence was reduced in both experimental sets:
in the cellular model, AP-NHm had a concentration-dependent anti-inflammatory effect; in rodents,
the high-dose AP-NHm 2 significantly reduced inflammatory cytokines release, both in co-treatment
and post-injury treatment. Most of the compounds present in AP-NHm have anti-inflammatory
properties, as extensively demonstrated by previous works on anti-inflammatory related disease,
not only on NASH or NAFLD [20,42–46].
Establishment of NASH in animals was reached by feeding with fat-rich diet, while in the cells the
syndrome was simulated by a lipid-overloading damage lasting 24 h. In both cases, many metabolic
alterations were induced and treatment with the multi-nutraceutical AP-NHm was able to reduce
them with good results. Insulin resistance is a clinical feature of metabolic syndrome and is part of
the pathologic picture of steatohepatitis as well [35,47]. It may manifest as reduced glucose uptake
from cells stimulated with insulin, since receptors do not respond appropriately to the hormone or it
may appear as persistent hyperglycemia following glucose load, because insulin is not able to exert its
hypoglycemic activity. In the in vitro model, co-treatments with all AP-NHm protected from insulin
resistance, while the same protective effect was reached during the post-injury recovery period only if
incubating cells with medium and high concentrated AP-NHm. Insulin activity was less impaired
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if animals were treated with AP-NHm 2, both in preventive and in post-injury protocols. Yao et al.
demonstrated that silymarin ameliorated insulin resistance in NASH rats and proposed that this
natural compound was able to modulate the expression of genes involved in visceral obesity, lipolysis
and gluconeogenesis [48]. The same role was not delineated for vitamin E since the biomolecule alone
seemed not able to repair damaged insulin response mechanisms [49]. Some mechanisms through
which DHA exerts this property emerged from studies on animals: anti-inflammatory effects and
modulation of the expression of related gene were proposed [50]; similarly, curbed insulin resistance
was obtained by supplementation with only CGA in animals with HFD-induced hepatic steatosis [51].
In the pathologic picture of non-alcoholic steatohepatitis, there are metabolic disorders going
along with it: hypertriglyceridemia, hypercholesterolemia and hyperglycemia. In the present study,
we proved that AP-NHm was able to protect from these metabolic alterations in both protocols: in the
cellular model intracellular triglycerides and cholesterol were reduced by co-treatment and post-injury
incubation in a concentration-dependent way; in mice the best results was obtained in co-treatment with
AP-NHm 2, while post-injury administrations were protective from 21–27 days after the establishment
of the pathology. Most of the components contained in the extracts of AP-NHm were reported to have
hypotriglyceremic, hypocholesterolemic and hypoglycemic properties and they were often related to
metabolic syndrome management. Cicero and co-authors [52] claimed lipid-lowering effects of some
nutraceuticals, pointing out also possible mechanisms of action. For example, silymarin was reported
to decrease lipid peroxidation of LDL, by acting as a radical scavenger, to inhibit HMG–CoA reductase
in vitro, to reduce hepatic total cholesterol and allow LDL uptake in vivo [52,53]. Vitamin E with its
anti-obesity, hypoglycemic and hypocholesterolemic properties was extensively reviewed for use in
metabolic syndrome management [54] and was supposed to act as a PPAR-receptor activator, inhibitor
of the enzyme HMG–CoA reductase and as a radical scavenger [52]. DHA is another nutraceutical
with lipid-lowering properties: Molinar-Toribio and his collaborators reported that combination of
EPA and DHA lowered LDL-cholesterol levels in a model of mouse metabolic syndrome [55] and,
on the basis of many supporting data, EFSA and American Heart Association sustained that DHA
can maintain normal blood TG levels or even reduce them by 25–30% [19,56]. DHA seemed to reduce
synthesis of VLDL and the synthesis of new TG, acting on substrate and enzymes. Preclinical and
clinical works confirmed the antidiabetic, anti-lipidemic, antioxidant, anti-inflammatory properties of
chlorogenic acid [57]; parthenolide was also proved to have anti-inflammatory and hypotriglyceremic
effects on the liver of rats [58]. The lipid-lowering properties of these functional foods present in
AP-NHm, described so far, are probably responsible for the loss of weight registered in the group of
rodents under AP-NHm 2 treatment, both in co-treatment and in post-injury therapeutic regimens.
This supposed mechanism of weight loss was supported by the absence of changes in food intake of the
slimmed down group, which was unvaried in all the others. The same weight loss was not observed
for all the explanted organs. AP-NHm 1 and 2 were able to reduce weight of fatty liver, an almost total
rescue was reported when mice were co-treated with the high-dose AP-NHm; heart and perigonadal
fat pad masses were downsized only by AP-NHm 2 in the preventive regimen. In parallel, the area of
adipocytes of this peculiar fat tissue was reduced in co-treatment with AP-NHm 2 and, in addition,
when the same mix was administered following the onset of NASH.
The final consequence of a severely altered lipid profile (triglycerides, total cholesterol, LDL and
HDL) and insulin resistance is hepatic steatosis, the precursor and pivotal marker of steatohepatitis.
As shown so far, metabolic alterations are so crucial in the pathologic picture of NASH, that Araujo and
her collaborators recently proposed a new positive definition of the pathology as metabolism-associated
steatohepatitis (MASH) [1], rather than a non-alcoholic disease. The above-mentioned insulin resistance
is also responsible for the impairment of lipid metabolism: it usually inhibits the activity of hormone
sensitive lipase (HSL) enzyme, but if the enzyme is deranged, triglyceride lipogenesis increases and
so do free fatty acids, thus reaching the liver where they accumulate [59]. In our study, hepatic
steatosis was histologically quantified by a steatosis index depending on the average percentage of
fat-accumulated hepatocytes in the parenchyma. Consistently with the lipid-lowering properties
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elucidated so far, our nutraceutical mixture AP-NHm was able to reduce the steatosis index in a
significant manner with both dosages in the co-treatment regimen and with the highest dosage in
the post-injury treatment; moreover, a similar pattern of protection was observed in vitro where fat
accumulation in hepatocytes was highlighted by O.D. analysis of Oil Red staining. Many studies
confirmed the peculiar ability of the main nutrients of our extracts, that are mixed with single bioactive
compounds, to reduce hepatic steatosis: silymarin was proved to attenuate insulin resistance and
hepatic steatosis after 3 months of treatment [60]; PIVENS trials demonstrated the therapeutic activity
of tocopherol, however limited in its administration due to safety concerns [7]; DHA was reported to be
protective in combination with the other polyunsaturated fatty acid EPA [16]; choline-deficiency and
its metabolism by gut microbiota were associated with hepatic steatosis development [61]; chlorogenic
acid injections reduced lipid accumulation in the liver of HFD fed mice [51]; parthenolide was not
directly reported to lower hepatic steatosis, but it was documented to reduce liver triacylglycerol
levels [58].
5. Conclusions
In the present study, a multicomponent mixture (AP-NHm) was planned for intervening on the
different features of non-alcoholic steatohepatitis. AP-NHm contained food bioactive molecules able
to prevent lipid load, reduce inflammatory processes, oxidative unbalance, the consequent glucose
metabolism alteration and hepatic steatosis. The nutraceutical formulation was tested in a model
of steatosis reproduced in vitro using the human hepatocellular carcinoma cell line HepG2 treated
with 0.5-mM oleic acid. AP-NHm was able to reduce the complex metabolic damages independent of
concentration, being active both in preventing alteration and in reducing damage. The nutraceutical
compounds also attenuated several metabolic and histological alterations induced in mice by HFD
nutrition. A prolonged feeding with a high fat provision evoked a steatohepatitis state characterized
by body weight increase, alteration of lipids and glucose levels, histopathologic damage of liver and
adipose tissue as well as a general oxidative and inflammatory condition. The tested formulation
induced hepatoprotective effects depending on the dosage: an almost complete prevention was
obtained when the high-dose AP-NHm 2 was daily administered from Day 1, in co-treatment regimen.
Nevertheless, it was noticed that a significative recovery was also obtained when treatments started
after the establishment of the metabolic alterations. Further studies are required to understand timing,
dosing and safety of this food extracts formulation, but our results set in the promising way of
nutraceutical therapy for NASH management.
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